Epigenomics Past Earnings Performance
Past criteria checks 0/6
Epigenomics has been growing earnings at an average annual rate of 8.5%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 10.7% per year.
Key information
8.5%
Earnings growth rate
39.3%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 10.7% |
| Return on equity | -853.4% |
| Net Margin | -3,644.5% |
| Next Earnings Update | 09 Nov 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Epigenomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -16 | 10 | 5 |
| 31 Mar 23 | 1 | -15 | 9 | 6 |
| 31 Dec 22 | 0 | -12 | 7 | 7 |
| 30 Sep 22 | 1 | -7 | 7 | 6 |
| 30 Jun 22 | 6 | -3 | 8 | 5 |
| 31 Mar 22 | 6 | -4 | 8 | 4 |
| 31 Dec 21 | 6 | -2 | 8 | 3 |
| 30 Sep 21 | 6 | -3 | 8 | 2 |
| 30 Jun 21 | 1 | -9 | 6 | 2 |
| 31 Mar 21 | 1 | -10 | 7 | 3 |
| 31 Dec 20 | 1 | -12 | 7 | 4 |
| 30 Sep 20 | 1 | -16 | 8 | 5 |
| 30 Jun 20 | 1 | -16 | 8 | 6 |
| 31 Mar 20 | 1 | -17 | 9 | 7 |
| 31 Dec 19 | 1 | -17 | 9 | 7 |
| 30 Sep 19 | 1 | -14 | 10 | 8 |
| 30 Jun 19 | 1 | -14 | 10 | 7 |
| 31 Mar 19 | 2 | -12 | 9 | 6 |
| 31 Dec 18 | 2 | -13 | 9 | 6 |
| 30 Sep 18 | 2 | -11 | 8 | 6 |
| 30 Jun 18 | 2 | -10 | 7 | 5 |
| 31 Mar 18 | 2 | -11 | 8 | 5 |
| 31 Dec 17 | 2 | -10 | 8 | 4 |
| 30 Sep 17 | 3 | -9 | 8 | 4 |
| 30 Jun 17 | 3 | -10 | 10 | 4 |
| 31 Mar 17 | 4 | -9 | 9 | 4 |
| 31 Dec 16 | 4 | -11 | 10 | 5 |
| 30 Sep 16 | 3 | -11 | 9 | 5 |
| 30 Jun 16 | 3 | -11 | 9 | 5 |
| 31 Mar 16 | 2 | -10 | 7 | 6 |
| 31 Dec 15 | 2 | -9 | 5 | 6 |
| 30 Sep 15 | 2 | -11 | 6 | 7 |
| 30 Jun 15 | 2 | -10 | 5 | 6 |
| 31 Mar 15 | 1 | -10 | 5 | 6 |
| 31 Dec 14 | 2 | -9 | 5 | 5 |
| 30 Sep 14 | 2 | -8 | 5 | 4 |
| 30 Jun 14 | 2 | -8 | 5 | 4 |
| 31 Mar 14 | 2 | -8 | 5 | 5 |
| 31 Dec 13 | 2 | -7 | 5 | 4 |
| 30 Sep 13 | 1 | -8 | 4 | 5 |
| 30 Jun 13 | 1 | -10 | 5 | 7 |
| 31 Mar 13 | 1 | -12 | 5 | 8 |
| 31 Dec 12 | 1 | -12 | 6 | 8 |
Quality Earnings: 0QXH is currently unprofitable.
Growing Profit Margin: 0QXH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0QXH is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare 0QXH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0QXH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 0QXH has a negative Return on Equity (-853.38%), as it is currently unprofitable.